C32.1: Malignant neoplasm of supraglottis
C32.1 is a billable, specific ICD-10-CM code for malignant neoplasm of supraglottis. It is valid for submission on a claim.
Check C32.1 with the rest of the claim: free scrubberExcludes2: not included here, but may coexist
The excluded condition is not part of this code, but a patient can have both. You may code both.
- malignant neoplasm of anterior surface of epiglottis (C10.1)
- malignant neoplasm of aryepiglottic fold or interarytenoid fold, hypopharyngeal aspect (C13.1)
- malignant neoplasm of aryepiglottic fold or interarytenoid fold, marginal zone (C13.1)
- malignant neoplasm of aryepiglottic fold or interarytenoid fold NOS (C13.1)
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Malignant neoplasm of aryepiglottic fold or interarytenoid fold, laryngeal aspect
- Malignant neoplasm of epiglottis (suprahyoid portion) NOS
- Malignant neoplasm of extrinsic larynx
- Malignant neoplasm of false vocal cord
- Malignant neoplasm of posterior (laryngeal) surface of epiglottis
- Malignant neoplasm of ventricular bands
Risk adjustment
C32.1 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 21 Lymphoma and Other Cancers0.671 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
C32.1 is named in 58 Medicare coverage policies: 58 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
- A52480Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article
- A53883Billing and Coding: Mohs Micrographic Surgery (MMS)
Code history
Unchanged in every release from FY2024 to FY2027.